Genetic Tech. (GENE), Complete Genomics (GNOM) See Profit-Taking Following Positive Cancer Report
Tweet Send to a Friend
Up)
Following a nice surge in share price Thursday on news that a recent study suggests genome screens on healthy people may offer key hints about their risks of cancer, Rosetta Genomics (Nasdaq: ROSG), Genetic Technologies Ltd. (Nasdaq: GENE), and Complete Genomics (Nasdaq: GNOM) are seeing investors take profits Friday.
Rosetta moved 3.3 percent while Complete saw a better jump at 12.9 percent and Genetic Tech rose 13 percent. Today, Rosetta is down 4 percent, Complete is off about 6 percent, and Genetic Tech is 7.3 percent lower.
For more on the report, click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Rosetta moved 3.3 percent while Complete saw a better jump at 12.9 percent and Genetic Tech rose 13 percent. Today, Rosetta is down 4 percent, Complete is off about 6 percent, and Genetic Tech is 7.3 percent lower.
For more on the report, click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- Controversial Abercrombie (ANF) CEO Back in Spotlight as Old Comments Surface
- Friday's Hot IPOs Get Even Hotter (MKTO) (DATA)
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
